Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 93

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 93
---
(365)Total research and development expenses$1,553 $2,151 $(598)$5,283 $8,529 $(3,246)

Three Months Ended September 30,Nine Months Ended September 30,20252024Change20252024ChangeGeneral and administrative expenses:Salaries and benefits related costs$225 $325 $(100)$688 $949 $(261)Legal fees130 113 17 371 545 (174)Audit fees72 113 (41)237 286 (49)Consulting145 234 (89)461 573 (112)Insurance185 157 28 501 718 (217)Other134 181 (47)347 523 (176)Stock-based compensation289 296 (7)944 1,259 (315)Total general and administrative expenses$1,180 $1,419 $(239)$3,549 $4,853 $(1,304)

Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

Research and development expenses during the three months ended September 30, 2025 decreased $0.6 million or 28%, compared to the three months ended September 30, 2024, and were primarily due to the following:

•Salaries and benefits related costs decreased $0.2 million as we did not accrue current year bonus accruals due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur.  

•Clinical trial expenses decreased $0.4 million primarily due to lower INVINCIBLE-3 Study costs.  In March 2025, we paused new site activations and patient enrollments in the INVINCIBLE-3 Study, due to funding constraints. Prior to this pause, the trial had enrolled 21 patients.  We will continue to treat all patients enrolled in this study in cooperation with our third-party contract research organizations during this pause, and once sufficient funding is obtained, we plan to restart site activations and patient enrollment.  

19

General and administrative expenses during the three months ended September 30, 2025 decreased $0.2 million or 17%, compared to the three months ended September 30, 2024, and were primarily due to the following:

•Salaries and benefits related costs decreased $0.1 million as we did not accrue current year bonus accrual